

**DACARBAZINE- dacarbazine injection, powder, lyophilized, for solution
Hikma Pharmaceuticals USA Inc.**

Dacarbazine for Injection, USP

Rx only

WARNING

It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.

- 1. Hemopoietic depression is the most common toxicity with dacarbazine (see WARNINGS).
- 2. Hepatic necrosis has been reported (see WARNINGS).
- 3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.
- 4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.

Boxed Warning


WARNING

It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.

1. Hemopoietic depression is the most common toxicity with dacarbazine (see **WARNINGS**).
2. Hepatic necrosis has been reported (see **WARNINGS**).
3. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.
4. In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.

DESCRIPTION

Dacarbazine for Injection, USP is a colorless to an ivory colored solid which is light sensitive. Each vial contains 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol. Dacarbazine is reconstituted and administered intravenously (pH 3.0 to 4.0). Dacarbazine is an anticancer agent. Chemically, dacarbazine is 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide with the following structural formula:



$C_6H_{10}N_6O$
M.W. = 182.19

CLINICAL PHARMACOLOGY

After intravenous administration of dacarbazine, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. The average cumulative excretion of unchanged dacarbazine in the urine is 40% of the injected dose in 6 hours. Dacarbazine is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations dacarbazine is not appreciably bound to human plasma protein.

In man, dacarbazine is extensively degraded. Besides unchanged dacarbazine, 5-aminoimidazole-4-carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine. AIC is not derived endogenously but from the injected dacarbazine, because the administration of radioactive dacarbazine labeled with ^{14}C in the imidazole portion of the molecule (dacarbazine-2- ^{14}C) gives rise to AIC-2- ^{14}C .

Although the exact mechanism of action of dacarbazine is not known, three hypotheses have been offered:

1. inhibition of DNA synthesis by acting as a purine analog
2. action as an alkylating agent
3. interaction with SH groups

INDICATIONS AND USAGE

Dacarbazine for Injection, USP is indicated in the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.

CONTRAINDICATIONS

Dacarbazine is contraindicated in patients who have demonstrated a hypersensitivity to it in the past.

WARNINGS

Hemopoietic depression is the most common toxicity with dacarbazine and involves primarily the leukocytes and platelets, although, anemia may sometimes occur. Leukopenia and thrombocytopenia may be severe enough to cause death. The possible bone marrow depression requires careful monitoring of white blood cells, red blood cells, and platelet levels. Hemopoietic toxicity may warrant temporary suspension or cessation of therapy with dacarbazine.

Hepatic toxicity accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death, has been reported. The incidence of such reactions has been low; approximately 0.01% of patients treated. This toxicity has been observed mostly when dacarbazine has been administered concomitantly with other anti-neoplastic drugs; however, it has also been reported in some patients treated with dacarbazine alone.

Anaphylaxis can occur following the administration of dacarbazine.

PRECAUTIONS

Hospitalization is not always necessary but adequate laboratory study capability must be available. Extravasation of the drug subcutaneously during intravenous administration may result in tissue damage and severe pain. Local pain, burning sensation, and irritation at the site of injection may be relieved by locally applied hot packs.

Carcinogenicity of dacarbazine was studied in rats and mice. Proliferative endocardial lesions, including fibrosarcomas and sarcomas were induced by dacarbazine in rats. In mice, administration of dacarbazine resulted in the induction of angiosarcomas of the spleen.

Pregnancy

Teratogenic effects; Pregnancy Category C

Dacarbazine has been shown to be teratogenic in rats when given in doses 20 times the human daily dose on day 12 of gestation. Dacarbazine when administered in 10 times the human daily dose to male rats (twice weekly for 9 weeks) did not affect the male libido, although female rats mated to male rats had higher incidence of resorptions than controls. In rabbits, dacarbazine daily dose 7 times the human daily dose given on Days 6 to 15 of gestation resulted in fetal skeletal anomalies. There are no adequate and well-controlled studies in pregnant women. Dacarbazine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for dacarbazine in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

ADVERSE REACTIONS

Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic

reactions. Over 90% of patients are affected with the initial few doses. The vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. Rarely, intractable nausea and vomiting have necessitated discontinuance of therapy with dacarbazine. Rarely, dacarbazine has caused diarrhea. Some helpful suggestions include restricting the patient's oral intake of food for 4 to 6 hours prior to treatment. The rapid toleration of these symptoms suggests that a central nervous system mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days.

There are a number of minor toxicities that are infrequently noted. Patients have experienced an influenza-like syndrome of fever to 39°C, myalgias and malaise. These symptoms occur usually after large single doses, may last for several days, and they may occur with successive treatments.

Alopecia has been noted as has facial flushing and facial paresthesia. There have been few reports of significant liver or renal function test abnormalities in man. However, these abnormalities have been observed more frequently in animal studies.

Erythematous and urticarial rashes have been observed infrequently after administration of dacarbazine. Rarely, photosensitivity reactions may occur.

OVERDOSAGE

Give supportive treatment and monitor blood cell counts.

DOSAGE AND ADMINISTRATION

Malignant Melanoma

The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals.

An alternate recommended dosage is 250 mg/square meter body surface/day I.V. for 5 days. Treatment may be repeated every 3 weeks.

Hodgkin's Disease

The recommended dosage of dacarbazine in the treatment of Hodgkin's disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks. An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days.

Dacarbazine 200 mg/vial is reconstituted with 19.7 mL of Sterile Water for Injection. The resulting solution contains 10 mg/mL of dacarbazine having a pH of 3.0 to 4.0. The calculated dose of the resulting solution is drawn into a syringe and administered *only* intravenously.

The reconstituted solution may be further diluted with 5% dextrose injection, or sodium chloride injection, and administered as an intravenous infusion.

After reconstitution and prior to use, the solution in the vial may be stored at 4°C for up to 72 hours or at normal room conditions (temperature and light) for up to 8 hours. If the reconstituted solution is further diluted in 5% dextrose injection or sodium chloride

injection, the resulting solution may be stored at 4°C for up to 24 hours or at normal room conditions for up to 8 hours.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.¹⁻⁷ There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration whenever solution and container permit.

HOW SUPPLIED

Dacarbazine for Injection, USP is supplied as follows:

NDC 0143-9245-10 200 mg/vial of sterile dacarbazine in boxes of 10.

Store in a refrigerator 2° to 8°C (36° to 46°F).

To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For Product Inquiry call 1-877-845-0689.

REFERENCES

- 1.Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402.
- 2.AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. JAMA, March 15, 1985.
- 3.National Study Commission on Cytotoxic Exposure Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, Sc. D., Director of Pharmacy Services, Rhode Island Hospital, 593 Eddy Street. Providence. Rhode Island 02902.
- 4.Clinical Oncological Society of Australia, Guidelines and recommendations for safe handling of antineoplastic agents. Med. J. Australia 1: 426-428, 1983.
- 5.Jones, R. B.. *et al.*: Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center. Ca-A Cancer Journal for Clinicians Sept./Oct., 258-263.1983.
- 6.American Society of Hospital Pharmacists technical assistance bulletin on handling cytotoxic drugs in hospitals. Am. J.Hosp. Pharm, 42: 131-137, 1985.
- 7.Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines). Am J Health-Syst Pharm, 53: 1669-1685, 1996.

Manufactured by

THYMOORGAN PHARMAZIE GmbH,
Schiffgraben 23, 38690 Goslar, Germany

Distributed by

Hikma Pharmaceuticals USA Inc.

Eatontown, NJ 07724 USA

Revised March 2020

127.207.024/01

PRINCIPAL DISPLAY PANEL

NDC 0143-9245-01 Rx only

**Dacarbazine
for Injection, USP
200 mg per vial**

Prepared as the citrate salt

**For Intravenous use
Cytotoxic Agent**

NDC 0143-9245-01 Rx only Sterile
Dacarbazine
for Injection, USP
200 mg per vial
Prepared as the citrate salt
For Intravenous use
Cytotoxic Agent

Usual Dosage: See package insert.
When reconstituted with 19.7 mL of Sterile Water for Injection, each mL of solution will contain 10 mg dacarbazine; 10 mg citric acid; and 3.75 mg mannitol.
Protect from light. Store in a refrigerator 2° to 8°C (36° to 46°F). Use within 8 hours of reconstitution. Discard unused portion.

Manufactured by
THYMORGAN PHARMAZIE GmbH, Germany
Distributed by Hikma, Eatontown, NJ 07724 USA

10100030149245003
LOT:
EXP:
127.206.050/01


NDC 0143-9245-10 Rx only
Dacarbazine for Injection, USP

200 mg per vial

Prepared as the citrate salt

**For Intravenous use
Cytotoxic Agent**

10 Single Dose Sterile Vials



DACARBAZINE

dacarbazine injection, powder, lyophilized, for solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0143-9245
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DACARBAZINE (UNII: 7GR28W0FJ1) (DACARBAZINE - UNII:7GR28W0FJ1)	DACARBAZINE	10 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
MANNITOL (UNII: 3OWL53L36A)	
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0143-9245-10	10 in 1 CARTON	08/08/2001	
1	NDC:0143-9245-01	20 mL in 1 VIAL; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA075812	08/08/2001	

Labeler - Hikma Pharmaceuticals USA Inc. (001230762)

Revised: 5/2024

Hikma Pharmaceuticals USA Inc.